Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Opsens Inc T.OPS

Alternate Symbol(s):  OPSSF

OpSens Inc. is engaged in physiological measurements such as Fractional Flow Reserve (FFR) and Diastolic Pressure Ratio (dPR) in the coronary artery disease market and in transcatheter aortic valve replacement (TAVR) in the structural heart market. The Company supplies an optical-based pressure guidewire (OptoWire), a guidewire used in the TAVR procedure (SavvyWire) and a wide range of miniature optical sensors to measure pressure and temperature to be used in a wide range of applications that can be integrated into other medical devices.

The Market Herald Price Sensitive
{{currentVideo.title}} {{currentVideo.relativeTime}}
{{currentVideo.storiesTitle}}:
{{story.companySymbol}}
{{story.companySymbol}} {{story.headline}}
< Previous bulletin
Next bulletin >
View modes: 

Developement time line on time...

Aortic valve stenosis; Product developement time line -Canada projected approbation by Canada Health ;End of April and Right on time for commercialization . -FDA September  -Europe Mid 2023...read more

RE:Canadian approval today!!!!

Excellent news . Congrats to Louis and his whole team , and to all the longs . Next up is the FDA .   rate and reply

Health Canada Approuve TAVR Guide wire

Hold on to your hat !  rate and reply

Canadian approval today!!!!

OPSENS ANNOUNCES HEALTH CANADA APPROVAL FOR ITS NEW TAVR GUIDEWIRE Canada NewswireApr 26, 2022 7:00 AM EDT QUEBEC CITY , April 26, 2022 ...read more

NR

https://www.stockwatch.com/News/Item/Z-C!OPS-3240153/C/OPS  rate and reply

RE:RE:RE:RE:RE:Breaking out

As per conference call , the company still expects Canadian approval as early as this quarter while FDA is @more likely in the second half of this year . Either way it@s all good for this hidden gem...read more

RE:RE:RE:RE:RE:Breaking out

As per conference call , the company still expects Canadian approval as early as this quarter while FDA is  more likely in the second half of this year . Either way it's all good for this...read more

RE:RE:RE:RE:Breaking out

Strong volume. Buyers are clearly expecting an earlier than expected approval by the FDA. This approval will open an entire new market for Opsens and will make it a perfect target for a takeover. GLTA...read more

RE:RE:RE:Breaking out

Whoever is buying they finally figured out the potential of this company. Could also be good news coming. We shall see.  rate and reply

RE:RE:Breaking out

It's been quite the bounce off that initial sell off from the earnings report . :)  rate and reply

Paradigm says Selloff Overdone

OpSens selloff has been overdone, says Paradigm By Geordie Carragher Published on April 19, 2022 Last Updated on April 19, 2022 Filed under:   All posts, Analysts, Health Stock:  ...read more

The market is blind to OPS

Next quarter is hopefully going to get this great opportunity to the $ to $5 range or more.  rate and reply

RE:conference call transcript

Great post! I think that the answers mr. Laflamme gave to the questions of the analyst just show the confidence he as in the company. The next six months will be very exciting. GLTA  rate and reply

conference call transcript

Potential catalyst - EuroPCR event, which is the biggest cardiovascular conference in Europe , May 17-20th Opsens Inc.’s (OPSSF) CEO Louis Laflamme on Q2 2022 Results – Earnings Call Transcript ...read more

Raymond James

4/14/2022 Raymond James  Set Price Target Strong-Buy C$6.00 +331.65%  rate and reply

RE:RE:Gap up !

Actually it closed up just shy of that 7%. As they say it's not where it begins but rather where it ends ;)   rate and reply

RE:Breaking out

On my stock analysis site there is a very strong support at 1.93   The resistance are all very weak at : 2.46 3.02 3.11 3.28 3.59  rate and reply

Breaking out

Just broke resistance which was at around 2.05 There's not much in the way going forward from what I can see. What do you think is the next resistance level 2.50$ or even 3$ maybe? And still, I...read more

RE:RE:This morning's La Presse

https://plus.lapresse.ca/screens/b2ede634-8f4e-4246-8a84-3f138afb3ec9__7C___0.html?utm_content=email&utm_source=lpp&utm_medium=referral&utm_campaign=internal+share I think you could not...read more